We developed a multidisciplinary, multifaceted intervention that significantly improved prescribing rates of SGLT2 inhibitors and GLP-1 RAs, medications that have been shown to reduce MACE, slow the progression of kidney disease, and improve outcomes in heart failure. The gene discussed is GLP1R; the disease is kidney disorder.